Logo for aTyr Pharma Inc

aTyr Pharma Investor Relations Material

Latest events

Logo for aTyr Pharma

Q3 2023

9 Nov, 2023
Logo for aTyr Pharma

Investor Presentation

1 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
aTyr Pharma, Inc. is a biotherapeutics company engaged in the discovery and development of medicines based on novel immunological pathways. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors.